期刊
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
卷 19, 期 -, 页码 4517-4537出版社
ELSEVIER
DOI: 10.1016/j.csbj.2021.07.041
关键词
Alzheimer's disease; MTDLs; Structure-based drug design; Polypharmacology; Tacrine; Acetylcholinesterase; NMDA receptor; Neuroprotection
资金
- Indian Council of Medical Research (ICMR) [BIC/11 (48) /2012]
- Japan Society for the Promotion of Science (JSPS) [16F16385]
- Kerala State Council for Science Technology and Environment (KSCSTE) [03/FSHP/2013/CSTE]
- Council of Scien-tific and Industrial Research (CSIR) [09/716 (0153) /2013-EMR-I]
- Department of Science and Technology (DST) [IF150638]
- DST-SERB [SB/FT/CS-079/20 14]
- Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram
- Grants-in-Aid for Scientific Research [16F16385] Funding Source: KAKEN
Research aimed to develop novel high affinity multitarget directed ligands (MTDLs) against AChE and NMDAR, with reduced hepatotoxicity, identified several promising compounds with potential therapeutic value, among which MTDL-201 appears to be a potential candidate for immediate preclinical evaluations.
The complex and multifactorial nature of neuropsychiatric diseases demands multi-target drugs that can intervene with various sub-pathologies underlying disease progression. Targeting the impairments in cholinergic and glutamatergic neurotransmissions with small molecules has been suggested as one of the potential disease-modifying approaches for Alzheimer's disease (AD). Tacrine, a potent inhibitor of acetylcholinesterase (AChE) is the first FDA approved drug for the treatment of AD. Tacrine is also a low affinity antagonist of N-methyl-D-aspartate receptor (NMDAR). However, tacrine was withdrawn from its clinical use later due to its hepatotoxicity. With an aim to develop novel high affinity multitarget directed ligands (MTDLs) against AChE and NMDAR, with reduced hepatotoxicity, we performed in silico structure-based modifications on tacrine, chemical synthesis of the derivatives and in vitro validation of their activities. Nineteen such derivatives showed inhibition with IC50 values in the range of 18.53 +/- 2.09 - 184.09 +/- 19.23 nM against AChE and 0.27 +/- 0.05 - 38.84 +/- 9.64 mu M against NMDAR. Some of the selected compounds also protected rat primary cortical neurons from glutamate induced excitotoxicity. Two of the tacrine derived MTDLs, 201 and 208 exhibited in vivo efficacy in rats by protecting against behavioral impairment induced by administration of the excitotoxic agent, monosodium glutamate. Additionally, several of these synthesized compounds also exhibited promising inhibitory activitiy against butyrylcholinesterase. MTDL-201 was also devoid of hepatotoxicity in vivo. Given the therapeutic potential of MTDLs in disease-modifying therapy, our studies revealed several promising MTDLs among which 201 appears to be a potential candidate for immediate preclinical evaluations. (C) 2021 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据